Genmab

E241390

Genmab is a Danish biotechnology company specializing in the development of antibody-based cancer therapies.

All labels observed (1)

Label Occurrences
Genmab canonical 1

How this entity was disambiguated

Statements (47)

Predicate Object
instanceOf biotechnology company
public company
collaboratesWith Janssen Biotech
Johnson & Johnson
Novartis
Roche
Seagen
country Denmark
focusesOnDisease cancer
hematologic malignancies
solid tumors
foundedBy Florian Schönharting
Jan G. J. van de Winkel
hasCEO Jan G. J. van de Winkel
hasOfficeLocation Japan
New Jersey, United States
surface form: New Jersey

Princeton
Netherlands
surface form: The Netherlands

Tokyo
United States of America
surface form: United States

Utrecht
headquartersLocation Copenhagen
Denmark
inception 1999
industry biotechnology
pharmaceuticals
ISIN DK0010272202
languageOfWorkOrName Danish
English
legalForm Aktieselskab
listedIn OMX Copenhagen 25
surface form: OMX Copenhagen 25 index
product daratumumab
surface form: Daratumumab

Ofatumumab
Teprotumumab
productType therapeutic antibodies
researchArea autoimmune diseases
immuno-oncology
specializesIn antibody-based cancer therapies
monoclonal antibodies
oncology
stockExchange Nasdaq Copenhagen
Nasdaq Global Select Market
technology antibody engineering
antibody-drug conjugates
bispecific antibodies
tickerSymbol GMAB
website https://www.genmab.com

How these facts were elicited

Referenced by (1)

Full triples — surface form annotated when it differs from this entity's canonical label.

Darzalex developedBy Genmab